FY2024 EPS Forecast for Prenetics Global Reduced by Analyst

Prenetics Global Limited (NASDAQ:PRE) – Cantor Fitzgerald cut their FY2024 earnings per share (EPS) estimates for Prenetics Global in a report issued on Thursday, March 6th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($3.52) per share for the year, down from their prior estimate of ($3.30). Cantor Fitzgerald currently has a “Overweight” rating and a $9.00 target price on the stock. The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share. Cantor Fitzgerald also issued estimates for Prenetics Global’s FY2025 earnings at ($2.12) EPS.

Prenetics Global Price Performance

NASDAQ:PRE opened at $4.86 on Monday. The stock has a market cap of $59.32 million, a P/E ratio of -1.22 and a beta of -0.31. The company has a fifty day moving average price of $5.45 and a 200 day moving average price of $4.99. Prenetics Global has a one year low of $2.85 and a one year high of $7.84.

Institutional Trading of Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new position in Prenetics Global Limited (NASDAQ:PRE) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned 0.10% of Prenetics Global at the end of the most recent reporting period. Institutional investors and hedge funds own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.